Consumers appropriately self-treat based on labeling for over-the-counter hydrocortisone - 21/08/11
Correspondence and reprint requests: Charles N. Ellis, MD, Department of Dermatology, University of Michigan Medical School, 1500 E Medical Center Dr, Ann Arbor, MI 48109-0314.Ann Arbor, Michigan; Seattle, Washington; Pittsburgh, Pennsylvania; and Bethesda, Maryland
Abstract |
Background |
Over-the-counter (OTC) topical corticosteroids, such as hydrocortisone cream (HC), are commonly used for the treatment of minor dermatological conditions. The safety and efficacy of such products are well documented, but details on patterns of use and self-treatment with HC in the OTC environment remain scarce.
Objective |
We sought to determine compliance with label directions of OTC HCs by examining self-reported patterns of OTC HC use in adults and children.
Methods |
A random digit-dialed telephone survey was conducted with 2000 US adults. Following identification of users of OTC HC in the last 6 months, respondents were asked questions about the conditions being treated with OTC HC and the frequency and duration of use in both adults and children.
Results |
Of adults completing the survey, 20% (n=396) had used OTC HC. In 83% of cases, the conditions treated were consistent with the OTC label. Use was limited; HC was applied ≤4 times daily in 98% of adult users and lasted ≤7 days in 92%. Patterns of pediatric use were similar and almost always consistent with the labeling. Of households with children, 25% (n=168) had used OTC HC to treat pediatric dermatological conditions. Of child users, 93% were 2 years of age or older, treatment was limited (97% applied HC ≤4 times daily and 94% of treatments lasted ≤7 days), and the conditions treated were appropriate in 86% of cases.
Limitations |
This telephone survey relied on respondents' recall and self-reporting. Our data on pediatric use of OTC HC are skewed toward treatment of younger children.
Conclusion |
The data suggest that OTC HC products are used for self-treatment in a limited and appropriate fashion that is likely to be safe in both adults and children.
Le texte complet de cet article est disponible en PDF.Plan
| Supported by GlaxoSmithKline Consumer Healthcare. Disclosure: Drs Ellis, Pillitteri, and Shiffman and Ms. Ertischek serve as consultants to GlaxoSmithKline Consumer Healthcare; Dr Ellis also serves as a consultant to other manufacturers of topical corticosteroids. Mr. Burton and Mr. Kyle are employed by GlaxoSmithKline Consumer Healthcare. |
Vol 53 - N° 1
P. 41-51 - juillet 2005 Retour au numéro
Article précédent
- American Board of Dermatology examination dates
- Psoriasis herpeticum: Three cases of Kaposi's varicelliform eruption in psoriasis
- Beth R. Santmyire-Rosenberger, Thomas P. Nigra
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?